Basel Medical Group Completes Overallotment Option Exercise in IPO

Basel Medical Group Ltd ( (BMGL) ) has issued an update.

Basel Medical Group Ltd announced the full exercise of the overallotment option by the underwriters of its initial public offering, resulting in the sale of an additional 330,750 ordinary shares at $4.00 per share. This move, which took place in March 2025, brought the total gross proceeds from the offering to $10,143,000. The company plans to use the proceeds for potential mergers and acquisitions, business expansion, and operational enhancements. The shares began trading on the Nasdaq Capital Market under the ticker symbol ‘BMGL’ on February 25, 2025, marking a significant step in Basel Medical’s growth strategy.

More about Basel Medical Group Ltd

Basel Medical Group Ltd is a Singapore-based provider specializing in orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, and neurosurgical treatments. With over 20 years of experience, the company has established strong relationships with corporations in the construction, marine, and oil & gas industries, positioning itself well within the private healthcare sector in Singapore and Southeast Asia.

YTD Price Performance: -9.01%

Average Trading Volume: 345,779

For a thorough assessment of BMGL stock, go to TipRanks’ Stock Analysis page.